This article is more than 5 years old. Information may no longer be current.

VIDEO: Preliminary study of Ozurdex for CME, proliferative retinopathy encouraging

ByAngelo Minnella, MD

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

BALTIMORE — At the Association for Research in Vision and Ophthalmology meeting here, Angelo Minnella, MD, of Catholic University of the Sacred Heart in Rome, discusses 6-month results of Ozurdex (dexamethasone intravitreal implant, Allergan) for the treatment of patients with macular edema and proliferative retinopathy.